Actualités

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $458.99, denoting a +1.28% move from the preceding trading day.

They have at least one thing in common: An exciting pipeline.

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

After helping scale Vertex Pharmaceuticals from $3 billion to $13 billion in revenue, CFO and COO Charles Wagner says finance leaders must build organizations for opportunities that haven’t emerged yet.

The death crosses flashing on both Hershey (NYSE: HSY) and Vertex Pharmaceuticals (NASDAQ: VRTX) are a bearish technical signal that Wall Street is openly ignoring. Analyst consensus on both stocks is solidly bullish, with double-digit implied upside to consensus targets, and the institutional bid keeps appearing even as the 50-day moving averages drift below the ... The Death Cross Is Lying: Why Wall Street Is Still Loading Up on Hershey and Vertex

Vertex Pharmaceuticals reported pivotal pediatric data for CASGEVY for young children with severe sickle cell disease and beta thalassemia. The company released positive long term and very early age group results for cystic fibrosis therapies ALYFTREK and TRIKAFTA. Vertex initiated regulatory reviews to expand indications into younger populations across multiple regions. These updates come with Vertex Pharmaceuticals (NasdaqGS:VRTX) shares trading at $445.04 and a value score of 4,...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $444.41, denoting a +2% move from the preceding trading day.

Is VRTX a good stock to buy? We came across a bullish thesis on Vertex Pharmaceuticals Incorporated on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on VRTX. Vertex Pharmaceuticals Incorporated’s share was trading at $445.77 as of June 9th. VRTX’s trailing and forward P/E were 26.46 and 23.47 respectively according to Yahoo […]

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $435.76, signifying a -2.25% move from its prior day's close.

A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.

Stock performance snapshot Vertex Pharmaceuticals (VRTX) is drawing investor attention after recent trading left the stock around US$446.83, with returns mixed across different periods and a longer term track record that stands in contrast to more recent moves. See our latest analysis for Vertex Pharmaceuticals. Recent trading has been choppy, with a 1-day share price return of 1.15% and a 30-day share price return of 4.49%, while the 1-year total shareholder return has slipped 0.81% and the...

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The market is underestimating these companies' long-term prospects.

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

If you are wondering whether Vertex Pharmaceuticals at around US$438 per share is priced attractively or already reflects its strengths, you are not alone. The stock has inched up 0.9% over the past week and 3.4% over the past month, while year to date it is down 3.0% and the 1 year return is also down 1.6%. This is set against a 31.1% gain over 3 years and a 109.6% gain over 5 years. These moves sit against a backdrop of ongoing interest in Vertex's pipeline and its position in treatments...

Vertex Pharmaceuticals recently reported that the FDA accepted its Biologics License Application for povetacicept in adults with immunoglobulin A nephropathy, with a PDUFA action date set for November 30, 2026, supported by Phase 3 data showing clinically meaningful reductions in proteinuria. This milestone marks a potential first commercial product in Vertex’s nephrology franchise, signaling progress in diversifying beyond its cystic fibrosis core. Next, we’ll explore how the FDA’s...

Vertex Pharmaceuticals (NASDAQ:VRTX) screens as a long-duration compounder because it sits on a global monopoly in cystic fibrosis therapies that generates substantial free cash, while Wall Street prices it closer to a generic large-cap biotech than to the cash-flow compounder its financials describe. For a retirement-focused investor who has been burned chasing momentum, this is ... Got $5,000? 1 Cash-Flow King to Buy and Hold Forever That Wall Street Is Completely Mispricing

VRTX moves closer to a potential nephrology launch as the FDA accepts its BLA for povetacicept in adults with IgAN, with a decision due in November 2026.

Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

VRTX stock falls 7.9% in three months as Journavx and Casgevy sales missed expectations, but CF growth, Alyftrek momentum and renal pipeline progress stand out.

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Regeneron Pharmaceuticals has underperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 4.1% return has trailed the S&P 500 by 6.2 percentage points.

Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the 12 Most Profitable Stocks to Invest In. On May 21, 2026, Vertex Pharmaceuticals (NASDAQ:VRTX) announced that Health Canada accepted for review a New Drug Submission for suzetrigine for the treatment of moderate-to-severe acute pain in adults. Vertex said suzetrigine is a selective NaV1.8 pain signal inhibitor and represents […]

Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.

If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading the way, the biotech space is more than worth exploring, especially as some of the AI benefits start to trickle downstream towards biotech ... These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth

The search is still on for an opioid alternative and many companies are betting on ion channel drugs to fill the gap.

Vertex Pharmaceuticals has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.